BeneMeat, a subsidiary of BTL, is a biotechnology company. Our main focus is on research and production of cultivated meat, covering also regulatory approvals and industrial scaling, with supporting research in cell line development and adaptation, fermentation and hydrolysis. BMT’s R&D infrastructure and proprietary technologies are available to support BTL’s, offering internal synergies for product development and supply.

Proprietary Technologies & Materials

Sourcing of biological materials for BTL applications, or providing technology to be produced by BTL.

• Cultivated Meat: Expertise and product access for strategic positioning in the sustainable food sector. Non-GMO (pet food ingredients), certified by regulatory authorities for EU, with preliminary approvals in UK and Singapore. GMO (human food ingredients) in approvals process.
• Spent media + sediment: Utilization of nutrient-rich residual media for nutraceuticals or agriculture.
• Precision Fermentation (FGF2 & HA): Production of non-animal origin FGF2 and Hyaluronic Acid for aesthetic medicine and wound care.
• Enzymatic Hydrolysis: Protein breakdown into bioavailable peptides for specialized nutrition or supplements
• Defensins: Application of antimicrobial peptides with potential in dermatology and immunology.
• Veterinary Development: Collaboration on combining BTL physical therapy devices with BMT biological supplements or pet food for enhanced treatment outcomes.